CompletedNCT06685965
RE03 study for sleep problems linked to PTSD
About this title
Read the official source — NCT06685965Researchers compared RE03 and placebo, tracking side effects to assess safety in people with PTSD.
Medication studyAges 18–64Switzerland
Understand this study
What did researchers investigate?
Researchers compared RE03 and placebo, tracking side effects to assess safety in people with PTSD.
Who was this study for?
This study was for people with PTSD. Listed age limits: 18 years to 64 years. Other eligibility criteria applied.
- Listed locations
- ZurichSee all locations and recruitment
- Study phase
- Phase 2Usually explores whether the intervention may work, while continuing to monitor safety.
Study information
Study start dateStarted: September 30, 2025
- Recruitment status
- Completed
- Enrollment listed in the registry
- 12
- Sponsor
- Reconnect Labs
- Sponsor type
- Unknown or unclear
- Study type
- Drug
- Intervention type
- Drug
- Study phase
- Phase 2Usually explores whether the intervention may work, while continuing to monitor safety.
- Locations
- Switzerland
- Age range
- From 18 Years to 64 Years
- Official registry ID
- NCT06685965
- Official title
Show the full official title
A Phase-2, Double-Blind, Randomized, Placebo-controlled, Crossover Dose-Finding, Laboratory-based Study to Evaluate Effects on Sleep and Safety of RE03 in PTSD Patients With Sleep Disturbances
Looking for a study you can join?
Explore recruiting studiesRecruitment & locations
CompletedThis badge reflects the study status reported by the registry. Check the registry for the latest information.
Zurich
Interested in joining this study?
Questions about this study
What did researchers investigate?
Researchers compared RE03 and placebo, tracking side effects to assess safety in people with PTSD.
Who is behind this study?
The study sponsor is Reconnect Labs.
Did this study involve medication?
Yes. The study involved medication, including RE03 and Placebo.
Who was this study for?
This study was for people with PTSD. Listed age limits: 18 years to 64 years. Other eligibility criteria applied.
